Company Overview and News

 
Genworth MI Canada Inc. (GMICF) CEO Stuart Levings on Q2 2018 Results - Earnings Call Transcript

2018-08-01 seekingalpha
Genworth MI Canada Inc. (OTCPK:GMICF) Q2 2018 Results Earnings Conference Call August 1, 2018 10:00 AM ET
GMICF MIC

1
Canadian Small Caps: Picks, Performance, Portfolio

2018-07-16 seekingalpha
There are compelling reasons to pick your own stocks here, but this requires more discipline and honesty than when buying an exchange traded fund.
TTTGF FXFLF FXFHF FAXXF MEQYF FRFHF FRFFF MRCBF FRFZF GCM.WT.A FAXRF FRFXF AOCIF BAM CDPYF BAMGF TPWRF VRRKF FRFGF TPRFF MIC GMICF GCM BAMKF TTR

1
Home Capital Group Is A Good Buy In 2018

2018-06-19 seekingalpha
Home Capital Group’s share price may trend higher if it can demonstrate consistent mortgage originations growth and increase its net interest margin.
HCG GMICF EQGPF EQB HMCBF MIC

 
Genworth MI Canada's (GMICF) CEO Stuart Levings on Q1 2018 Results - Earnings Call Transcript

2018-05-05 seekingalpha
Genworth MI Canada Inc. (OTCPK:GMICF) Q1 2018 Earnings Conference Call May 2, 2018 10:00 AM ET
GMICF MIC

 
Genworth MI Canada Inc. 2018 Q1 - Results - Earnings Call Slides

2018-05-03 seekingalpha
The following slide deck was published by Genworth MI Canada Inc. in conjunction with their 2018 Q1 earnings call.
GMICF MIC

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to TSX:MIC / Genworth Mi Canada Inc. on message board site Silicon Investor.

Quantum Economics.......2012 and Beyond Quantum Economics.......2012 and Beyond Quantum Economics.......2012 and Beyond Formerly About Advanced Micro Devices Formerly About Advanced Micro Devices Formerly About Advanced Micro Devices
Mainstream Politics and Economics Mainstream Politics and Economics Mainstream Politics and Economics Hurricanes: Tracking and Economics Hurricanes: Tracking and Economics Hurricanes: Tracking and Economics
Microsoft Corp. - Moderated (MSFT) Microsoft Corp. - Moderated (MSFT) Microsoft Corp. - Moderated (MSFT) Severe weather events, climate change and economics Severe weather events, climate change and economics Severe weather events, climate change and economics
ENPH - Enphase, worldu0027s leading solar microinverter player ENPH - Enphase, worldu0027s leading solar microinverter player ENPH - Enphase, worldu0027s leading solar microinverter player Microcap Kitchen Canadian Stocks Microcap Kitchen Canadian Stocks Microcap Kitchen Canadian Stocks
Severe Weather and the Economic Impact Severe Weather and the Economic Impact Severe Weather and the Economic Impact The Microcap Basement The Microcap Basement The Microcap Basement